Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + dexamethasone
- Development stage
- Preclinical
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravitreal
01
Overview
Aflibercept + dexamethasone is a combination therapy that simultaneously delivers an anti-vascular endothelial growth factor (anti-VEGF) agent and a corticosteroid. This combination is particularly beneficial for patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who do not respond adequately to anti-VEGF monotherapy. The combination has also shown promise in treating diabetic macular edema (DME). Researchers have developed drug delivery systems (DDS) that can release both medications simultaneously from a single system, potentially reducing the treatment burden by decreasing the number of required injections. In conventional treatment, patients typically require monthly/bimonthly injections of anti-VEGF and semi-annual injections of corticosteroid.
- Brand names
- Combo-DDS
- Other names
- Combo-DDS
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)GR (Glucocorticoid receptor)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on aflibercept + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + dexamethasone.